



|  |            |          |        |           |     |          |      |       |
|--|------------|----------|--------|-----------|-----|----------|------|-------|
| PubMed   | Nucleotide | Protein  | Genome | Structure | PMC | Taxonomy | OMIM | Books |
| Search PubMed                                  | for        | Go Clear |        |           |     |          |      |       |
| Limits Preview/Index History Clipboard Details |            |          |        |           |     |          |      |       |

|         |          |          |      |         |      |
|---------|----------|----------|------|---------|------|
| Display | Abstract | Show: 24 | Sort | Send to | Text |
|---------|----------|----------|------|---------|------|

☐ 1: Biull Eksp Biol Med 1993 Sep;116(9):311-3

[Related Articles, Links](#)

Entrez PubMed

**[The mite allergen and allergoid stimulation of histamine secretion by mast cells]**

[Article in Russian]

PubMed  
Services

**Khlgtatian SV, Perova NA, Berzhets VM.**

Rat peritoneal mast cells were incubated with serum from highly mite-sensitive patients. It was demonstrated that exposure of passive sensitized mast cells to allergen from mites *Dermatophagoides farinae* induced the release of histamine. Exposure of mast cells to 10 micrograms/ml and 50 micrograms/ml mite allergen resulted in an increase of histamine secretion to 48% of the basal level. The allergoid (formaldehyde-modified mite allergen) had poor histamine-releasing activity compared to allergen. The allergoid (50 micrograms/ml) induced a 2.5-fold decrease in histamine release. The allergen at the same concentrations and the same release as allergen in dose 0.1 microgram/ml.

Related  
Resources

PMID: 7509651 [PubMed - indexed for MEDLINE]

|         |          |          |      |         |      |
|---------|----------|----------|------|---------|------|
| Display | Abstract | Show: 20 | Sort | Send to | Text |
|---------|----------|----------|------|---------|------|

Write to the Help Desk

NCBI | NLM | NIH  
Department of Health & Human Services  
Freedom of Information Act | Disclaimer

Feb 19 2003 14:38:47



|  |            |         |        |           |     |          |      |       |
|--|------------|---------|--------|-----------|-----|----------|------|-------|
| PubMed   | Nucleotide | Protein | Genome | Structure | PMC | Taxonomy | OMIM | Books |
| Search PubMed                                  | for        |         |        |           |     |          | Go   | Clear |
| Limits Preview/Index History Clipboard Details |            |         |        |           |     |          |      |       |
| Display Abstract Show 20 Sort Send to Text     |            |         |        |           |     |          |      |       |

☐ 1: Schweiz Rundsch Med Prax 1990 Apr 3;79(14):430-6

Related Articles, Links

Entrez PubMed

**[Hyposensitization in pollinosis. Results of a 3-year controlled study with 2 depot-allergoid grass pollen extracts: aluminum hydroxide-adsorbed allergoid and tyrosine-adsorbed allergoid]**

[Article in German]

PubMed  
Services**Muhlethaler K, Wuthrich B, Peeters AG, Terki N, Girard JP, Frank E.**

Dermatologische Klinik, Universitat Zurich.

Related  
Resources

For controlled hyposensitization treatment over a period of three years 36 patients with confirmed grass pollen sensitization had been selected in 1986 and randomly distributed to receive preseasonal injection therapy: 23 patients were treated with an average of seven AGD (aluminium-adsorbed allergoid) injections, and 13 patients had received six TA (tyrosine-adsorbed allergoid) injections. Evaluation of the trial data collected during three years of preseasonal treatment showed the following results of tolerance and efficacy: Systemic side-reactions registered during therapy were only mild and transient and occurred in the average after 3% of the AGD injections and after 10% of the TA injections. Local reactions over 5 cm diameter were registered after 7% in the AGD group and after 9% in the TA group. Before therapy there was no significant difference ( $p$  greater than 0.05) between the groups; after three years of therapy the AGD injections had resulted in a mean net rise of specific IgG of 220% (significant,  $p = 0.001$ ); during the same time, TA injections had resulted in a final net increase of 10% (not significant,  $p$  greater than 0.05). Both treatment forms did not lead to any statistically relevant changes of specific IgE values. After three years of hyposensitization treatment, patients of both groups had improved; but an advantage was documented for patients treated with AGD on the basis of scores for objective assessment as well as for registered symptom and medication scores.

Publication Types:

- Clinical Trial
- Randomized Controlled Trial

PMID: 2188335 [PubMed - indexed for MEDLINE]